Lobbying disclosures · Lobbying report
GILD: third_quarter 2026 lobbying report
Issues related to healthcare, including improving patient access to advanced immunology therapies; Issues related to policies affecting biopharma products pricing, coverage and access in Medicare and Medicaid; Issues related to funding for HIV and HCV screening, linkage to care and treatment; Issues related to breast cancer screening.
Follow GILD- Became public
- Oct 18, 2026, 1:43 PM EDT
- Event / period date
- Not stated
- Collected
- Nov 11, 2026, 6:18 AM EST
Why this is connected
Exact legal-name match: GILEAD SCIENCES, INC. (https://www.sec.gov/Archives/edgar/data/882095/).
Reported lobbying amounts
Income: $80,000.00
These are different reporting measures. They are not added together or treated as spending on one particular bill.
Source evidence
Read the source excerpt or record
{"url":"https://lda.gov/api/v1/filings/164d2634-1cc8-41e2-b6d6-fa454b01f2bb/","filing_uuid":"164d2634-1cc8-41e2-b6d6-fa454b01f2bb","filing_type":"Q3","filing_type_display":"3rd Quarter - Report","filing_year":2026,"filing_period":"third_quarter","filing_period_display":"3rd Quarter (July 1 - Sep 30)","filing_document_url":"https://lda.gov/filings/public/filing/164d2634-1cc8-41e2-b6d6-fa454b01f2bb/print/","filing_document_content_type":"text/html","income":"80000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Zachary Williams","dt_posted":"2026-10-18T13:43:27-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"777 6th Street NW","registrant_address_2":"8th Floor","registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20001","registrant":{"id":400976792,"url":"https://lda.gov/api/v1/registrants/400976792/","house_registrant_id":null,"name":"FORBES-TATE","description":"Government Relations Firm.","address_1":"777 6th Street NW","address_2":"8th Floor","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20001","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"ZACHARY WILLIAMS","contact_telephone":"+1 202-638-0125","dt_updated":"2026-07-20T16:54:02.529740-04:00"},"client":{"id":205130,"url":"https://lda.gov/api/v1/clients/205130/","client_id":1522,"name":"GILEAD SCIENCES, INC.","general_description":"Specialty biopharmaceutical company.","client_government_entity":false,"client_self_select":null,"state":"CA","state_display":"California","country":"US","country_display":"United States of America","ppb_state":"CA","ppb_state_display":"California","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2020-02-01"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Issues related to healthcare, including improving patient access to advanced immunology therapies; Issues related to policies affecting biopharma products pricing, coverage and access in Medicare and Medicaid; Issues related to funding for HIV and HCV screening, linkage to care and treatment; Issues related to breast cancer screening.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":72734,"prefix":null,"prefix_display":null,"first_name":"BARRETT","nickname":null,"middle_name":null,"last_name":"THORNHILL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":68997,"prefix":null,"prefix_display":null,"first_name":"CYNTHIA","nickname":null,"middle_name":null,"last_name":"BROWN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":57902,"prefix":null,"prefix_display":null,"first_name":"ELIZABETH","nickname":null,"middle_name":null,"last_name":"GREER","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"},{"id":12,"name":"White House Office"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}Congressional trading in GILD
These disclosures provide context. Their presence does not establish a link between a trader and the event.
- Jul 21, 2026$1K–$15K
Sen. Alan Armstrong (R-OK)
$1K–$15K · Traded Mar 27, 2026 · disclosed Jul 21, 2026 · filed 116 days later
Committee overlap: HELP - Jun 19, 2026$1K–$15K
Rep. Jared Moskowitz (D-FL-23)
$1K–$15K · Traded May 6, 2026 · disclosed Jun 19, 2026
- Jun 19, 2026$1K–$15K
Rep. Jared Moskowitz (D-FL-23)
$1K–$15K · Traded May 6, 2026 · disclosed Jun 19, 2026 · Dependent
- Feb 26, 2026$1K–$15K
Rep. Josh Gottheimer (D-NJ-5)
$1K–$15K · Traded Jan 27, 2026 · disclosed Feb 26, 2026 · Joint
- Oct 10, 2025$1K–$15K
Rep. Val T. Hoyle (D-OR-4)
$1K–$15K · Traded Sep 23, 2025 · disclosed Oct 10, 2025 · Spouse
- Sep 12, 2025$1K–$15K
Rep. Val T. Hoyle (D-OR-4)
$1K–$15K · Traded Oct 29, 2024 · disclosed Sep 12, 2025 · Spouse · filed 318 days later
- Jun 22, 2025$15K–$50K
Rep. Jefferson Shreve (R-IN-6)
$15K–$50K · Traded May 12, 2025 · disclosed Jun 22, 2025
- Jun 18, 2025$1K–$15K
Rep. Marjorie Taylor Greene (R-GA-14)
$1K–$15K · Traded Jun 6, 2025 · disclosed Jun 18, 2025
Original documents control. Public records can be amended, and company connections may require interpretation. Nothing here is investment advice.